greeksoup/ stocks
Stocks / India / ZYDUSLIFE / Q1 FY2025

Zydus Lifesciences Ltd. Q1 FY2025 results: revenue ₹6,208 crore, up 20.8% on the year

Zydus Lifesciences Ltd. (ZYDUSLIFE) reported consolidated revenue from operations of ₹6,208 crore for Q1 FY2025, the quarter ended 30 June 2024, up 20.8% on the same quarter a year earlier. Profit after tax was ₹1,482 crore, up 30.8% on the year, and earnings per share ₹14.11. The figures are the company's own, from the unaudited results it filed with NSE on 9 August 2024.

Revenue from operations₹6,208 croreup 20.8%
Profit after tax₹1,482 croreup 30.8%
EPS₹14.11
QuarterQ1 FY2025ended 30 June 2024

The quarter, against the one before and a year earlier

LineQ1 FY2025Q4 FY2024A year earlierChange on the year
Revenue from operations6,2085,534n/an/a
Other income63156n/an/a
Total income6,2715,690n/an/a
Cost of materials consumed1,1161,210n/an/a
Purchases of stock-in-trade522543n/an/a
Changes in inventories-52-142n/an/a
Employee benefit expense884837n/an/a
Finance costs3235n/an/a
Depreciation, depletion and amortisation215205n/an/a
Other expenses1,6541,455n/an/a
Total expenses4,3714,143n/an/a
Profit before exceptional items and tax1,9001,547n/an/a
Exceptional items00n/an/a
Profit before tax1,9001,547n/an/a
Current tax654465n/an/a
Deferred tax-218-144n/an/a
Total tax436321n/an/a
Profit after tax1,4821,246n/an/a
Attributable to owners of the parent1,42064n/an/a
Other comprehensive income-24-170n/an/a
Total comprehensive income1,4591,076n/an/a
EPS, basic₹14.11₹11.69n/an/a
EPS, diluted₹14.11₹11.69n/an/a

₹ crore except per share.

Quarterly results, the last 12 quarters

Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Sales4,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,5878,017
Expenses3,4163,6174,1434,3714,0344,1424,7174,8084,5115,5385,6646,798
Operating profit1,1461,1021,6312,0841,4611,3882,1262,0882,0161,8162,5541,929
OPM %26%24%29%34%28%26%33%32%33%26%34%24%
Other income543815663685881155109111134106
Interest920353225327785101130123156
Depreciation184195205215234229238238302360508555
Exceptional items000000-2200-34-85-398-18
Profit before tax1,0079261,5471,9001,2711,1841,6721,9211,6871,3531,6601,307
Tax %22%23%21%23%29%15%25%23%27%29%19%27%
Net profit8037901,2461,4829201,0261,2441,5211,2391,0231,341990
EPS in ₹₹7.91₹7.80₹11.69₹14.11₹9.06₹10.17₹11.64₹14.58₹12.51₹10.36₹12.65₹9.35
FilingNSENSENSENSENSENSEFilingFilingFilingFilingFilingFiling

₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.

Source

Unaudited consolidated results for the quarter ended 30 June 2024, filed with NSE on 9 August 2024: the result statement. All of Zydus Lifesciences Ltd.'s results: NSE company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install